Holy Stone Healthcare Co., Ltd
5 clinical trials · Sponsor
◉ Watch Holy Stone Healthcare Co., Ltd
| Record | Firm | Date |
|---|---|---|
| Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer (NCT06039202) | Holy Stone Healthcare Co., Ltd | 2024-01-01 |
| First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors (NCT03616574) | Holy Stone Healthcare Co., Ltd | 2019-04-09 |
Track Holy Stone Healthcare Co., Ltd automatically
Every clearance here is in the API, with alerts when new ones post.